(Colorado Newsline) Democratic leaders, health care providers and consumer advocates praised a Colorado board’s decision last week to cap the price of a prescription drug used to treat rheumatoid ...

Last year, the board voted to deem Enbrel “unaffordable,” setting up a months-long process of determining whether it should ...

Colorado became the first state in the nation to set a price cap on a specific medication last week, following a unanimous ...

Medicare was authorized to negotiate prices it will pay for Part D drugs. Enbrel, the original version of etanercept, was among the first 10 drugs to be subject to negotiations. The negotiated price ...

Alston & Bird allege their client has suffered more than $1 billion in lost sales from being unable to manufacture a biosimilar product in the United States to compete with Amgen's blockbuster Enbrel ...

In a first-in-the-nation move, a Colorado panel voted to limit what health plans in the state will pay for a costly arthritis ...

Alston & Bird represent plaintiff Sandoz Inc. in an antitrust lawsuit against Amgen. Munger, Tolles & Olson and Kaufman & Canoles represent Amgen in a related case in the Eastern District of Virginia.

AbbVie is on the rebound after a sell-off on concerns about the pending FDA decision for a biosimilar drug. Humira and Enbrel are among the top-selling drugs to be copycatted but biosimilars are ...

Upper payment limits (UPL) present clear challenges and dangers to patients because of its potential impact on access to life ...

Non-medical switching policies that mandate biosimilar use for inflammatory arthritis do not appear to increase the use of ...

Colorado regulators have approved a dramatic price cap on one of the nation’s best-selling drugs, cutting its price to less than one-third of its previous level, in a novel attempt by a state to ...